Expression of hypothetical proteins in human fetal brain: Increased expression of hypothetical protein 28.5 kDa in Down syndrome, a clue for its tentative role

Molecular Genetics and Metabolism

Volumn 78, Issue 4, 2003, Pages 295-301

  Engidawork, Ephrem ^a   Gulesserian, Talin ^a   Fountoulakis, Michael ^b   Lubec, Gert ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Brain; Fetal Down syndrome; Hypothetical proteins; Two dimensional electrophoresis

Indexed keywords

M PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; BRAIN; CONTROLLED STUDY; DOWN SYNDROME; FEMALE; FETUS; FRAGMENTATION REACTION; HUMAN; HUMAN TISSUE; HYPOTHESIS; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS;

EID: 0037389843     PISSN: 10967192     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1096-7192(03)00046-5     Document Type: Article

References (35)

1. Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T., Park H.-.S.et al. The DNA sequence of human chromosome 21. Nature. 405:2000;311-319.
2. Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S., Ansorge W., Böcher M., Blöcker H., Bauersachs S., Blum H., Lauber J., Düsterhöft A., Beyer A., Köhrer K., Strack N., Mewes H.-W., Ottenwälder B., Obermaier B., Tampe J., Heubner D., Wambutt R., Korn B., Klein M., Poustka A. Towards the catalog of human genes and proteins: sequencing and analysis of 500 novel complete protein coding human cDNAs. Genome Res. 11:2001;422-435.
3. Orengo C.A., Bray J.E., Buchan D.W.A., Harrison A., Lee D., Pearl F.M.G., Sillitoe I., Todd A.E., Thornton J.M. The CATH protein family database: a resource for structural and functional annotation of genomes. Proteomics. 2:2002;11-21.
4. Becker L., Mito E., Takashima S., Onodera K. Growth and development of the brain in Down syndrome. Prog. Clin. Biol. Res. 373:1991;133-152.
5. Wisniewski K.E. Down syndrome children often have brain with maturation delay, retardation of growth, and cortical dysgenesis. Am J. Med. Genet. 7(Suppl):1990;274-281.
6. Fountoulakis M. Proteomics: current technologies and application in neurological disorders and toxicology. Amino Acids. 21:2001;363-381.
7. Engidawork E., Lubec G. Protein expression in Down syndrome brain. Amino Acids. 21:2001;331-361.
8. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
9. Langen H., Röder D., Juranville J.-.F., Fountoulakis M. Effect of the protein application mode and the acrylamide concentration on the resolution of protein spots separated by two-dimensional gel electrophoresis. Electrophoresis. 18:1997;2085-2090.
10. Fountoulakis M., Langen H. Identification of proteins by matrix assisted laser desorption ionization mass spectrometry following in-gel digestion in low salt, non-volatile buffer and simplified peptide recovery. Anal. Biochem. 250:1997;153-156.
11. Berndt P., Hobohm U., Langen H. Reliable automatic protein identification from matrix-assisted laser desorption/ionization mass spectrometric peptide fingerprints. Electrophoresis. 20:1999;3521-3526.
12. Fountoulakis M., Juranville J.F., Dierssen M., Lubec G. Proteomic analysis of the fetal brain. Proteomics. 2:1999;1547-1576.
13. Bernert G., Fountoulakis M., Lubec G. Manifold decreased protein levels of martin, 3 reduced motor protein HMP and hlark in fetal Down's syndrome brain. Proteomics. 2:2002;1752-1757.
14. Bajo M., Fruehauf J., Kim S.H., Fountoulakis M., Lubec G. Proteomic evaluation of intermediary metabolism enxyme proteins in fetal Down's syndrome fetal cortex. Proteomics. 2:2002;1539-1546.
15. Weitzdoerfer R., Fountoulakis M., Lubec G. Reduction of actin-related protein complex 2/3 in fetal Down syndrome brain. Biochem. Biophys. Res. Commun. 293:2002;836-841.
16. Gulesserian T., Kim S.H., Fountoulakis M., Lubec G. Aberrant expression of centractin and capping proteins, integral constituents of the dynactin complex, in fetal Down syndrome brain. Biochem. Biophys. Res. Commun. 291:2002;62-67.
17. Dhermy D. The spectrin superfamily. Biol. Cell. 71:1991;249-254.
18. Trave G., Pastore A., Hyvonen M., Saraste M. The C-terminal domain of alpha-spectrin is structurally related to calmodulin. Eur J. Biochem. 227:1995;35-42.
19. Rohwer A., Kittstein W., Marks F., Gschwendt M. Cloning, expression, and characterization of an A6-related protein. Eur. J. Biochem. 263:1999;518-525.
20. Loftus B.J., Kim U.J., Sneddon V.P., Kalush F., Brandon R., Fuhrmann J., Mason T., Crosby M.L.et al. Genome duplications and other features in 12. Mb of DNA sequence from human chromosome 16p and 16q Genomics. 60:1999;295-308.
21. Janssen D.B., Pries F., van der Ploeg J.R. Genetics and biochemistry of dehalogenating enzymes. Annu. Rev. Microbiol. 48:1994;163-191.
22. Koonin E.V., Tatusov R.L. Computer analysis of bacterial haloacid dehalogenases defines a large superfamily of hydrolases with diverse specificity. Application of an iterative approach to database search. J. Mol. Biol. 244:1994;125-132.
23. Teissier E., Fennrich S., Strazielle N., Daval J.L., Ray D., Schlosshauer B., Ghersi-Egea J.F. Drug metabolism in vitro organotypic and cellular models of mammalian central nervous system: activities of membrane-bound epoxide hydrolase and NADPH-cytochrome P-450 reductase. Neurotoxicology. 19:1998;347-355.
24. Seidegard J., DePierre J.W. Microsomal hydrolase. Properties, regulation, and function. Biochim. BioPhyis. Acta. 695:1983;251-270.
25. Pinot F., Grant D.F., Beetham J.F., Parker A.G., Borhan B., Landt S., Jones A.D., Hammock B.D. Molecular and biochemical evidence for the involvement of the Asp-333-His-523 pair in the catalytic mechanism of soluble epoxide hydrolases. J. Biol. Chem. 270:1995;7968-7974.
26. Farin F.M., Janssen P., Quigley S., Abbott D., Hassett C., Smith-Weller T., Franklin G.M., Swanson P.D., Longstreth W.T. Jr., Omiecinski C.J., Checkoway H. Genetic polymorphisms of microsomal and soluble epoxide hydrolases and the risk of Parkinson's disease. Pharmacogenetics. 11:2001;703-708.
27. Busciglio J., Yankner B.A. Apoptosis and increased generation of active oxygen species in Down syndrome neurons in vitro. Nature. 378:1995;37-44.
28. Gulesserian T., Engidawork E., Fountoulakis M., Lubec G. Antioxidant proteins in fetal brain: superoxide dismutase-1 (SOD-1) protein is not overexpressed in fetal Down syndrome. J. Neural. Transm. 61(Suppl):2001;71-84.
29. Odetti P., Angelini G., Dapino D., Zaccheo D., Garibaldi S., Dagna-Bricarelli F., Piombo G., Perry G., Smith M., Traverso N., Tabaton M. Early glycoxidation damage in brains from Down's syndrome. Biochem. Biophys. Res. Commun. 243:1998;849-851.
30. Kang K.W., Ryu J.H., Kim S.G. Activation of phsphatidylinositol 3-kinase by oxidative stress leads to induction of microsomal epoxide hydrolase in H4IIE cells. Toxicol. Lett. 121:2001;191-197.
31. Aravind L., Koonin E.V. The STAS domain- a link between anion transporters and anti-sigma factor antagonists. Curr. Biol. 10:2000;R53-R55.
32. Hastbacka J., de la Chapelle A., Mahtani M.M., Clines G., Reeve-Daly M.P., Daly M., Hamilton B.A., Kusumi K., Trivedi B.et al. The diastrophic dysplasia gene encodes a novel sulfate transporter: positional cloning by fine structure linkage disequilibrium mapping. Cell. 78:1994;1073-1087.
33. Hastbacka J., Superti-Furga A., Wilcox W.R., Rimoin D.L., Cohn D.H., Lander E.S. Atelosteogenesis type II is caused by mutations in the diastrophic dysplasia sulfate-transporter gene (DTDST): evidence for a phenotypic series involving three chondrodysplasias. Am. J. Hum. Genet. 58:1996;255-262.
34. Everett L.A., Glasser B., beck J.C., Idol J.R., Buchs A., Heyman M., Adawi F., Hazani E., Nassir E., Baxevanis A.D., Sheffield V.C., Green E.D. Pendered syndrome is caused by mutation in a putative sulfate-transporter gene (PDS). Nat. Genet. 17:1997;411-422.
35. Scott D.A., Wang R., Kreman T.M., Sheffield V.C., Karniski L.P. The pendered syndrome gene encodes a chloride-iodide transport protein. Nat. Genet. 21:1999;440-443.